Immunogenicity and safety of a pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate combination vaccine (Pentaxim™) with hepatitis B vaccine

Indian Pediatrics

Volumn 46, Issue 11, 2009, Pages 975-982

  Dutta, A K ^a   Verghese, V P ^b   Pemde, H K ^a   Mathew, L G ^b   Ortiz, Esteban ^c  

^a LADY HARDINGE MEDICAL COLLEGE   (India)

^b CHRISTIAN MEDICAL COLLEGE   (India)

^c SANOFI PASTEUR   (France)

Author keywords

EPI schedule; Immunogenicity; Pentavalent combined vaccine; Primary series; Safety

Indexed keywords

BACTERIAL VACCINE; BACTERIUM ANTIBODY; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; PENTAXIM; RECOMBINANT HEPATITIS B VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS VACCINE;

ANOREXIA; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYING; DIPHTHERIA; DISEASE SEVERITY; DROWSINESS; DRUG SAFETY; FEMALE; FEVER; GROUPS BY AGE; HEPATITIS B; HUMAN; IMMUNOGENICITY; IMMUNOREACTIVITY; INCIDENCE; INFANT; INFLUENZA; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERTUSSIS; PHASE 3 CLINICAL TRIAL; POLIOMYELITIS; PROSPECTIVE STUDY; SIDE EFFECT; SWELLING; TENDERNESS; TERTIARY HEALTH CARE; TETANUS; VOMITING;

ANTIBODIES, BACTERIAL; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; FEMALE; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HEPATITIS B VACCINES; HUMANS; INDIA; INFANT; MALE; POLIOVIRUS VACCINE, INACTIVATED; PROSPECTIVE STUDIES; VACCINES, COMBINED; VACCINES, CONJUGATE;

EID: 70449411334     PISSN: 00196061     EISSN: 00196061     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Indian Academy of Pediatrics Committee on Immunization (IAPCOI). Consensus recommendations on immunization, 2008. Indian Pediatr 2008; 45: 635-648.
2. Shah R, Raghu MB, Shivananda A, Mangayarkarashi S, Rao I, Rao R, et al. Immunogenicity and safety of an indigenously developd DTPw-hepatitis B combination vaccine in Indian infants. Indian Pediatr 2008; 45: 819-823.
3. Polio Eradication Committee, Indian Academy of Pediatrics, Vashishtha VM, John TJ, Agarwal RK, Kalra A. Universal immunization program and polio eradication in India. Indian Pediatr 2008; 45: 807-813.
4. Mittal SK, Mathew JL. IPV revisited...yet again. Indian Pediatr 2008; 45: 390-395.
5. Edwards KM, Decker M. Pertussis vaccines. In: Plotkin SA, Orenstein WA, editors. Vaccines. 5th ed. Philadelphia PA: Saunders Co.; 2008. p. 467-518.
6. WHO. Vaccine preventable diseases monitoring system: Country profiles. Available from: URL: http://www.who.int/vaccines/globalsummary/immunization/ countryprofileselect.cfm. Accessed January 15, 2009.
7. WHO Position Paper. Pertussis vaccines. Weekly Epidemiol Rec 2005; 80: 29-40.
8. WHO. United Nations prequalified vaccines (WHO list of vaccines for purchase by UN agencies as of August 2008). Available from: URL: http://www.who.int/immunization-standardsn/vaccine-quality/pq-suppliers/en/ index.html. Accessed October 29, 2008.
9. Mallet E, Hoffenbach A, Salomon H, Blondeau C, Fritzell B. Primary immunization with combined, acellular DTaP-IPV-Act-HIB vaccine given at 2-3-4 or 2-4-6 months of age. The 15th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID), Paris, France 1997.
10. Capeding RM, Cadorna-Carlos J, Book-Montellano M, Ortiz E. Immunogenicity and safety of a DTaP-IPV//PRP∼T combination vaccine at 6, 10,14 weeks of age (EPI schedule) and concomitant Hepatitis B vaccination at birth, 6, 14 or 6, 10, 14 weeks of age. WHO Bulletin 2008; 86: 443-451.
11. Carlsson RM, Claesson BA, Selstam U, Fagerlund E, Granstrom M, Blondeau C, et al. Safety and immunogenicity of a combined diphtheria, tetanus, acellular pertussis-inactivated polio vaccine- Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age. Pediatr Infect Dis J 1998; 17: 1026-1033.
12. Lagos R, Kotloff, KL Hoffenbach A, San Martin O, Abrego P, Ureta AM, et al. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six month-old Chilean infants. Pediatr Infect Dis J 1998; 17: 294-304.
13. Kanra G, Selier T, Yurdakök K, Yavuz T, Baskan S, Ulukol B, et al. Immunogencity study of a combined diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis vaccine used to reconstitute a freeze-dried Haemophilus influenzae type b vaccine (DTacP-IPV//PRP-T) administered simul-taneously with a hepatitis B vaccine at two, three and four months of life. Vaccine 2000; 18: 947-954.
14. Vidor E, Plotkin SA. Immunogenicity of a two-component (PT & FHA) acellular pertussis vaccine in various combinations. Human Vaccines 2008; 4: 328-340.
15. Swedish Institute for Infectious Disease Control. Pertussis surveillance in Sweden with enhanced follow-up of cohorts immunized with acellular pertussis vaccines 2007 Appendix 2 SP-MSD. Available from: URL: http://www. smittskyddsinstitutet.se/upload/10-y%20report-app%202-%20SP%20MSD.pdf. Accessed December 4, 2008.
16. Olin P, Hallander HO. Marked decline in pertussis followed reintroduction of pertussis vaccination in Sweden. Euro Surveill 1999; 4:128-129.
17. Gustafsson L, Hessel L, Storsaeter J, Olin P. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Pediatr 2006; 118: 978-984.
18. Cherian T, Thomas N, Raghupathy P, Durot I, Dutta A. Safety and immunogenicity of Haemophilus influenzae type B vaccine given in combination with DTwP at 6, 10 and 14 weeks of age. Indian Pediatr 2002; 39: 427-436.
19. Acharya D, Bhave S, Joshi V, Bavdekar A, Pandit A. Haemophilus influenzae type b vaccine in India: need and timing, immunogenecity and tolerance. Indian Pediatr 1997; 34: 9-15.
20. Greco D, Salmaso S, Mastrantonio P, Giuliano M, Tozzi AE, Anemona A, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med 1996; 334: 341-348.
21. Olin P, Rasmussen F, Gustafsson L, Hallander H, Heijbel H. Randomised controlled trial of two-component, three component, and five component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Lancet 1997; 350: 1569-1577. (Pubitemid 28036599)